Dhairya A. Patel

Array ( [id] => 18895613 [patent_doc_number] => 20240011098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/901481 [patent_app_country] => US [patent_app_date] => 2022-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 95857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254856 [patent_doc_number] => 12427189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Vaccine comprising epitope of heat shock protein, and use thereof [patent_app_type] => utility [patent_app_number] => 17/885255 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 44 [patent_no_of_words] => 14253 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17885255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302474 [patent_doc_number] => 12448452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Methods and compositions relating to anti-PD1 antibody reagents [patent_app_type] => utility [patent_app_number] => 17/870010 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 6 [patent_no_of_words] => 32096 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302474 [patent_doc_number] => 12448452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Methods and compositions relating to anti-PD1 antibody reagents [patent_app_type] => utility [patent_app_number] => 17/870010 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 6 [patent_no_of_words] => 32096 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302474 [patent_doc_number] => 12448452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Methods and compositions relating to anti-PD1 antibody reagents [patent_app_type] => utility [patent_app_number] => 17/870010 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 6 [patent_no_of_words] => 32096 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302474 [patent_doc_number] => 12448452 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Methods and compositions relating to anti-PD1 antibody reagents [patent_app_type] => utility [patent_app_number] => 17/870010 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 6 [patent_no_of_words] => 32096 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142159 [patent_doc_number] => 20230016003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => SINGLE CELL PATHOLOGY ANALYSIS OF TUMOUR SAMPLES [patent_app_type] => utility [patent_app_number] => 17/866587 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 463 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990171 [patent_doc_number] => 20220356208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => PEPTIDES AND COMBINATION THEREOF FOR USE IN THE IMMUNOTHERAPY AGAINST CANCERS [patent_app_type] => utility [patent_app_number] => 17/860821 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17860821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003536 [patent_doc_number] => 20220362302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/843412 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343586 [patent_doc_number] => 20240252549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => COMPOSITIONS AND METHODS TO TRANSFECT, TEST, AND TREAT SKIN CELLS [patent_app_type] => utility [patent_app_number] => 18/565023 [patent_app_country] => US [patent_app_date] => 2022-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9457 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18565023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318335 [patent_doc_number] => 20240239878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => BINDING MOLECULE AGAINST DLL3 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/289007 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19250179 [patent_doc_number] => 20240201167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => THE IMMUNOMODULATORY LIGAND B7-1 MEDIATES SYNAPTIC REMODELING BY P75NTR [patent_app_type] => utility [patent_app_number] => 18/556488 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140524 [patent_doc_number] => 20240139316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => USE OF OREGOVOMAB AND BEVACIZUMAB, PACLITAXEL, CARBOPLATIN FOR TREATMENT OF BRCA-WILD TYPE PLATINUM SENSITIVE RECURRENT [patent_app_type] => utility [patent_app_number] => 18/280981 [patent_app_country] => US [patent_app_date] => 2022-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18280981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882771 [patent_doc_number] => 20220298248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => Treatment of Cancers Lacking EGFR- Activating Mutations [patent_app_type] => utility [patent_app_number] => 17/687984 [patent_app_country] => US [patent_app_date] => 2022-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17647 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17687984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20142829 [patent_doc_number] => 12377144 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen [patent_app_type] => utility [patent_app_number] => 17/686238 [patent_app_country] => US [patent_app_date] => 2022-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 61 [patent_no_of_words] => 53905 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902752 [patent_doc_number] => 20240018237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ROR1 BINDING PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/260556 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642291 [patent_doc_number] => 20220170029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => APPLICATION OF NAT1 GENE AS SCREENING MARKER IN GENETIC TRANSFORMATION OF OOMYCETE [patent_app_type] => utility [patent_app_number] => 17/675083 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20349818 [patent_doc_number] => 20250346670 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => METHODS OF TREATING CANCER BY ADMINISTERING A NEOADJUVANT PD-1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/264799 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18264799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760078 [patent_doc_number] => 20220233690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CYTOKINE RELEASE SYNDROME [patent_app_type] => utility [patent_app_number] => 17/587501 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595385 [patent_doc_number] => 20220144958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => METHOD FOR SUPPRESSING REGULATORY T CELL INFILTRATION BY CCR4 INHIBITION AND METHOD FOR TREATING CANINE NEOPLASTIC DISEASE [patent_app_type] => utility [patent_app_number] => 17/587648 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587648 [rel_patent_id] =>[rel_patent_doc_number] =>)